Previous 10 | Next 10 |
Provention Bio, Inc. (PRVB) Q2 2020 Earnings Conference Call August 06, 2020, 08:00 ET Company Participants Andrew Drechsler - CFO Ashleigh Palmer - Co-Founder, President, CEO & Director Jason Hoitt - Chief Commercial Officer Francisco Leon - Co-Founder & Chief Scientif...
Provention Bio (NASDAQ: PRVB ) : Q2 GAAP EPS of -$0.45 misses by $0.18 . Cash, cash equivalents and marketable securities of $172.2M as of June 30, 2020. Shares +2.6% . Press Release More news on: Provention Bio, Inc., Earnings news and commentary, Healthcare stocks news, ...
OLDWICK, N.J. , Aug. 6, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the second quarter ended June 30, 2020 and provided a busin...
Data by YCharts Introduction Provention Bio ( PRVB ) is a US biotechnology company developing biologics that target immune-mediated diseases. PRVB's therapeutic initiatives target endocrine diseases, infectious diseases, and respiratory diseases. This report will serve as a thor...
OLDWICK, N.J. , July 30, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its second quarter 2020 financial results on Thursd...
Investing in clinical-stage biotech stocks is risky. While positive results from clinical trials can send shares flying, the probability of a newly developed drug successfully making its way through all phases of the clinical trial process and earning regulatory approval is low. Still, picking t...
OLDWICK, N.J. , June 30, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today a change in the format of its 2020 Annual Meeting of Stockholders (the "Annual Meeting") ...
OLDWICK, N.J. , June 29, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has been added to the broad-market Russell 3000® Index and the small-cap Rus...
OLDWICK, N.J. , June 22, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the closing of the previously announced public offering of 7,590,000 shares of common sto...
Provention Bio (NASDAQ: PRVB ) +1% prices its public offering of 6.6M common shares at $14.50 per share for gross proceeds of $95.7M. More news on: Provention Bio, Inc., Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Provention Bio, Inc. (NASDAQ: PRVB) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 3.14% on the day to $24.99. Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and comme...
2023-04-06 11:29:16 ET What Are Penny Stocks? The market for penny stocks has continued growing over the last few years. But what are these stocks in the first place? The general definition of penny stocks includes shares of companies trading below $5. Making money with penny st...
NEW YORK, NY / ACCESSWIRE / March 23, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Seagen Inc. (NASDAQ:SGEN)'s sale t...